Search results
Results from the WOW.Com Content Network
Currently, however, inflammatory pseudotumor designates a large and heterogeneous group of soft tissue tumors that includes inflammatory myofibroblastic tumor, plasma cell granuloma, xanthomatous pseudotumor, solitary mast cell granuloma, inflammatory fibrosarcoma, [4] pseudosarcomatous myofibroblastic proliferation, myofibroblastoma ...
Medical imaging may suggest but cannot prove that a tumor is MFB. Mammography, computed tomography scans, and magnetic resonance imaging of mammary [1] [12] and extramammary [1] [13] MFB typically show well-defined and well-circumscribed tumors which in almost all cases have no calcifications; these results suggest that the tumor is not malignant but do not indicate which type it might be.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Intranodal palisaded myofibroblastoma (IPM) is a rare primary tumour of lymph nodes, that classically presents as an inguinal mass. [ 1 ] It afflicts predominantly males of middle age.
Trodusquemine is an aminosterol (polyamine steroid conjugate) that inhibits protein tyrosine phosphatase 1B (PTP1B) activity. [1] The compound exhibits broad-spectrum antimicrobial activity [2] and numerous regenerative, neuroprotective, anti-atherosclerotic, antitumor, antiangiogenic, antiobesity, and anxiolytic properties. [3]
Thienodiazepine BET inhibitors were discovered in a phenotypic drug screen by scientists at Yoshitomi Pharmaceuticals (now Mitsubishi Tanabe Pharma) in the early 1990s, and their potential both as anti-inflammatories and anti-cancer agents noted.
The injectable medication Zepbound, manufactured by Eli Lilly, was approved by the FDA on November 8 to treat chronic obesity. - Eli Lilly/AP/FILE Wen: These medications both appear to work well.
Antisense therapy is a form of treatment that uses antisense oligonucleotides (ASOs) to target messenger RNA (mRNA). ASOs are capable of altering mRNA expression through a variety of mechanisms, including ribonuclease H mediated decay of the pre-mRNA, direct steric blockage, and exon content modulation through splicing site binding on pre-mRNA. [1]